AUTOFLEET/BLUEBIRD/ABEAM
22.4.2021 15:02:11 CEST | Business Wire | Press release
Bluebird Group (Bluebird), Indonesia’s leading taxi operator, has engaged with Autofleet and ABeam Consulting for a project to support its national fleet of over 23,000 vehicles with Autofleet’s Vehicle-as-a-Service platform. Bluebird and Autofleet have entered into a commercial agreement that is scheduled to roll out for vehicles operating in Jakarta and the surrounding area as soon as Q2 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005276/en/
By leveraging the Autofleet platform, Bluebird will be able to optimize its fleet’s vehicle placement, match and predict drivers based on demand forecasting to reduce empty rides, optimize allocation efficiency, allow for greater availability in traditionally under-served areas, reduce customer ETAs and improve overall customer experience. Autofleet is ingesting data from rides requested through the operator’s digital app and through traditional street hailing. These inputs are combined with real-time traffic data, weather forecasts, local events and other data points for increased demand prediction accuracy.
“The demand for mobility services has evolved, and it poses challenges that can only be solved by a combination of AI driven technology, and best in class operations. It is Bluebird’s value and commitment to deliver such customer-centric innovation through sustainable cooperation with our strategic partners, Autofleet and ABeam Consulting,” said Paul Soegianto, Chief Strategy Officer of PT Blue Bird Tbk.
In business for nearly 50 years, Bluebird serves millions of passengers every month. The fleet includes regular taxis (Bluebird & Pusaka), executive taxis (Silverbird), limousines and car rentals (Goldenbird), bus charters (Bigbird) and logistics (Birdkirim) among others. Autofleet’s platform will be integrated into the current dispatch infrastructure, supporting Bluebird, Silverbird and Birdkirim services in its first phase. In the longer term, the collaboration will inform Bluebird’s expanded activities in logistics and delivery services as well as exploration of new mobility infrastructure including electric vehicle (EV) charging.
“We are excited to partner with Bluebird, already a leader in mobility services in Southeast Asia, and apply the Autofleet platform to power current operations and prepare the business for future strategy and growth,” said Kobi Eisenberg, CEO at Autofleet. “Deploying Autofleet's platform will keep Bluebird at the cutting edge of the mobility industry, providing an outstanding customer experience, in a very competitive market.”
“ABeam Consulting is thrilled to support and expand Bluebird’s innovative services through AI and machine learning to increase operational efficiency,” said Tatsuya Kamoi, CEO at ABeam Consulting. “With our deep expertise in Mobility as a Service, we will support Bluebird’s operations and apply industry best practices to stay competitive with leading rideshare companies.”
In September 2020, Autofleet and ABeam Consulting entered a partnership to offer a comprehensive solution that supports Mobility as a Service (MaaS) projects end-to-end from the proposal stage to system implementation. Following projects in Japan and Cambodia, the engagement with Bluebird was secured through a year-long competitive proposal process and represents the largest commercial fleet management opportunity arising from the partnership to date.
About Autofleet
Autofleet provides the leading Vehicle-as-a-Service platform for fleets to optimize existing operations and to seamlessly launch new business models from existing assets. The platform leverages advanced machine-learning algorithms for demand prediction, optimized placement and matching, automated pit-stop management and in/de-fleeting, and more. For more information, please visit https://www.autofleet.io/
.
About ABeam Consulting
ABeam Consulting Ltd., headquartered in Tokyo having 6,600 people serve more than 1,100 clients throughout Asia, in the Americas and Europe with its 28 offices since 1981, providing consulting services across various industries and with an expertise in digital transformation services that create strategic advantage, improve business processes, leverage technology innovation and enhance organizational performance.
Please contact and visit us under https://www.abeam.com/jp/en for more details.
About Bluebird
Established in 2001, PT Blue Bird Tbk (BIRD), is a public transportation company catering to passengers and providing other land transportation services. PT Blue Bird Tbk's 15 subsidiaries are found in 18 major cities around the country, namely Jakarta, Depok, Tangerang, Bekasi, Cilegon, Medan, Manado, Bandung, Palembang, Balikpapan, Padang, Pangkalpinang, Batam, Bali, Lombok, Semarang, Surabaya, Pekanbaru, Makassar, Solo and Yogyakarta.
Bluebird is committed to always provide safe, reliable, and comfortable transportation with easy accessibility for its customers. Companies extensive network covers more than 600 exclusive taxi outlets placed in malls, shopping centers and other strategic places. Serving millions of passengers every month.
Since going public on the Indonesia Stock Exchange in 2014, PT Blue Bird Tbk has gained status as a reliable and trustworthy transportation partner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005276/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
